CH594671A5 - - Google Patents

Info

Publication number
CH594671A5
CH594671A5 CH1668372A CH1668372A CH594671A5 CH 594671 A5 CH594671 A5 CH 594671A5 CH 1668372 A CH1668372 A CH 1668372A CH 1668372 A CH1668372 A CH 1668372A CH 594671 A5 CH594671 A5 CH 594671A5
Authority
CH
Switzerland
Application number
CH1668372A
Inventor
Susan Constance Garsi Bicknell
David Hartley
Lawrence Henry Charles Lunts
Alexander William Oxford
Original Assignee
Allen & Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen & Hanburys Ltd filed Critical Allen & Hanburys Ltd
Publication of CH594671A5 publication Critical patent/CH594671A5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CH1668372A 1971-11-19 1972-11-16 CH594671A5 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5375071A GB1400999A (en) 1971-11-19 1971-11-19 Imidazo-triazine compounds and their use in therapeutic compositions

Publications (1)

Publication Number Publication Date
CH594671A5 true CH594671A5 (xx) 1978-01-13

Family

ID=10468856

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1668372A CH594671A5 (xx) 1971-11-19 1972-11-16

Country Status (18)

Country Link
US (1) US3840537A (xx)
JP (1) JPS563873B2 (xx)
AT (1) AT321923B (xx)
AU (1) AU472127B2 (xx)
BE (1) BE791025A (xx)
CA (1) CA990292A (xx)
CH (1) CH594671A5 (xx)
DE (1) DE2255172A1 (xx)
DK (1) DK138691B (xx)
ES (1) ES408736A1 (xx)
FR (1) FR2160407B1 (xx)
GB (1) GB1400999A (xx)
IE (1) IE37046B1 (xx)
IL (1) IL40686A (xx)
NL (1) NL7215646A (xx)
PH (1) PH9669A (xx)
SE (1) SE402915B (xx)
ZA (1) ZA727532B (xx)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1174431A2 (de) 1997-11-12 2002-01-23 Bayer Aktiengesellschaft 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren
US6930108B2 (en) 2001-07-23 2005-08-16 Bayer Healthcare Ag Use of 2-alkoxyphenol-substituted imidazotriazinones
US6943163B2 (en) 1998-06-20 2005-09-13 Bayer Aktiengesellschaft 7-Alkyl and cycloalkyl-substituted imidazotriazinones

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DE2314488C3 (de) * 1973-03-23 1979-01-04 C.H. Boehringer Sohn, 6507 Ingelheim 8-(2,6-Dichlorphenyl)-7-(4-chlorphenyl)-5-oxo-233,8-tetrahydro-imidazo [1,2-a] -s-triazin, Verfahren zu dessen Herstellung und dieses enthaltene Arzneimittel
DE2335193A1 (de) * 1973-07-11 1975-01-30 Hoechst Ag Bis-triazinobenzimidazole und ihre herstellung
US4107307A (en) * 1977-02-03 1978-08-15 American Cyanamid Company Imidazo [1,5-d]-as-triazine-4(3H)-ones and thiones
USRE30511E (en) * 1977-02-03 1981-02-10 American Cyanamid Company Imidazo[1,5-d]-as-triazine-4(3H)-ones and thiones
US4115572A (en) * 1977-02-03 1978-09-19 American Cyanamid Company Imidazo-[1,5-d]-as-triazin-1(2H)-ones and method of ameliorating asthma
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4107308A (en) * 1977-10-18 1978-08-15 American Cyanamid Company Imidazo[1,5-d]-as-triazines
US4308384A (en) * 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
HU187474B (en) * 1981-11-18 1986-01-28 Gyogyszerkutato Intezet,Hu Process for producing new spiro-pyrazole-square bracket-1,5-d-square bracket closed-square bracket-1,2,4-square bracket closed-triazine derivatives
US4395547A (en) * 1982-02-10 1983-07-26 American Cyanamid Co. Process for preparing 1-substituted-6-n-propyl-8-methylimidazo[1,5-d]-as-triazin-4(3H)-ones
AU622330B2 (en) * 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
EP1107747A4 (en) 1998-08-26 2003-04-23 Smithkline Beecham Corp COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
AU777012B2 (en) * 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
JP4540295B2 (ja) * 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−フェニル置換イミダゾトリアジノンの新しい用途
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
GB0113344D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
EP1608656B1 (en) * 2003-04-01 2009-06-03 SmithKline Beecham Corporation Imidazotriazine compounds for the treatment of cancer diseases
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
SI1951724T1 (sl) * 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc Kondenzirani biciklični mTOR inhibitorji
EP2167057A1 (en) * 2007-06-13 2010-03-31 Bayer HealthCare AG Pde inhibitors for the treatment of hearing impairment
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
US20180044343A1 (en) * 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
WO2017000276A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017204316A1 (ja) * 2016-05-27 2017-11-30 塩野義製薬株式会社 ５－オキソ－１，２，４－トリアジン誘導体およびその医薬組成物

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1174431A2 (de) 1997-11-12 2002-01-23 Bayer Aktiengesellschaft 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren
BG65257B1 (bg) * 1997-11-12 2007-10-31 Bayer Aktiengesellschaft 2-фенил-заместени имидазотриазинони като фосфодиестеразни инхибитори
EP2295436A1 (de) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
US6943163B2 (en) 1998-06-20 2005-09-13 Bayer Aktiengesellschaft 7-Alkyl and cycloalkyl-substituted imidazotriazinones
US6930108B2 (en) 2001-07-23 2005-08-16 Bayer Healthcare Ag Use of 2-alkoxyphenol-substituted imidazotriazinones
US7276504B2 (en) 2001-07-23 2007-10-02 Bayer Healthcare Ag Use of 2-alkoxyphenyl-substituted imidazotriazinones

Also Published As

Publication number Publication date
JPS563873B2 (xx) 1981-01-27
NL7215646A (xx) 1973-05-22
IL40686A (en) 1975-12-31
JPS4857993A (xx) 1973-08-14
IE37046L (en) 1973-05-19
AU472127B2 (en) 1976-05-20
GB1400999A (en) 1975-07-16
IL40686A0 (en) 1972-12-29
DK138691C (xx) 1979-03-26
US3840537A (en) 1974-10-08
IE37046B1 (en) 1977-04-27
AT321923B (de) 1975-04-25
CA990292A (en) 1976-06-01
AU4819172A (en) 1974-05-16
FR2160407A1 (xx) 1973-06-29
BE791025A (fr) 1973-05-07
DE2255172A1 (de) 1973-05-24
DK138691B (da) 1978-10-16
ES408736A1 (es) 1976-03-01
PH9669A (en) 1976-02-10
FR2160407B1 (xx) 1975-10-17
SE402915B (sv) 1978-07-24
ZA727532B (en) 1973-07-25

Similar Documents

Publication Publication Date Title
ATA136472A (xx)
AR196074A1 (xx)
AU2658571A (xx)
AU2691671A (xx)
AU2485671A (xx)
AU3005371A (xx)
AU2952271A (xx)
AU2941471A (xx)
AU2894671A (xx)
AU2742671A (xx)
AU2684071A (xx)
AU2564071A (xx)
AU2473671A (xx)
AU2755871A (xx)
AU2486471A (xx)
AU3038671A (xx)
AU2503871A (xx)
AU3025871A (xx)
AU2577671A (xx)
AU2588771A (xx)
AU2654071A (xx)
AU2456871A (xx)
AU2669471A (xx)
AU2455871A (xx)
AU2684171A (xx)

Legal Events

Date Code Title Description
PL Patent ceased